Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
Brianna Askew, Carolyn Revta, Irfan Qureshi, Yuqi Qiu et al.
Citations
3 citations
Journal
Alzheimer s Research & Therapy
Topics
Dementia and Cognitive Impairment Research
Field-Weighted Citation Impact (FWCI)
4.41
article
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease
Brianna Askew, Carolyn Revta, Irfan Qureshi, Yuqi Qiu, Howard Feldman, Lia Donahue, Diane M. Jacobs, Stephen Kaplita, Sophie Stukas, Cheryl L. Wellington, Vladimir Coric, Karen Messer, David P. Salmon, Gabriel C. Léger, James Brewer
article en
3 citations
Abstract
No abstract available for this paper.
Publication Tag
Alzheimer s Research & TherapyVol. 17(1)
Institutions
University of British Columbia (CA), University of California San Diego (US), Biohaven Pharmaceuticals (United States) (US), Alzheimer’s Disease Neuroimaging Initiative (US), International Collaboration On Repair Discoveries (CA), East China Normal University (CN)
Funders
National Institutes of Health, University of California, San Diego, National Institute on Aging
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease — Brianna Askew, Carolyn Revta, et al. · Alzheimer s Research & Therapy (2025) | TGRS Research Map | TGRS